Jounce Therapeutics, Inc.
DelistedCIK 1640455fmd_0QEQDS7A1NTPNM9CM2DZGHGF7SManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2015 to Dec 31, 2022, 29 periods
Latest annual · FY2022
Millions- Operating income
- (52)
- Net income
- (51)
- Free cash flow
- (30)
Latest quarter · Q4 FY2022
Millions- Operating income
- 50
- Net income
- 51
- Free cash flow
- 59
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2017 to FY2022
- n/m
Jounce Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$52.2 million | -$91.1 million | 10-K 2023-03-10 · proof | |
| Net income | -$50.9 million | -$90.9 million | 10-K 2023-03-10 · proof | |
| Cash from operating activities | -$28.9 million | -$83.5 million | 10-K 2023-03-10 · proof | |
| Free cash flow | -$29.8 million | -$83.9 million | 10-K 2023-03-10 · proof | |
| Total assets | $212.6 million | $252.7 million | -15.9% | 10-K 2023-03-10 · proof |
| Total liabilities | $29.4 million | $28.9 million | +1.9% | 10-K 2023-03-10 · proof |
| Cash and cash equivalents | $150.6 million | $95.5 million | +57.6% | 10-K 2023-03-10 · proof |
- What was Jounce Therapeutics, Inc.'s operating income in fiscal 2022?
- Jounce Therapeutics, Inc. reported operating income of -$52.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$91.1 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2023. SEC
- What was Jounce Therapeutics, Inc.'s net income in fiscal 2022?
- Jounce Therapeutics, Inc. reported net income of -$50.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$90.9 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2023. SEC
- What was Jounce Therapeutics, Inc.'s cash from operating activities in fiscal 2022?
- Jounce Therapeutics, Inc. reported cash from operating activities of -$28.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$83.5 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2023. SEC
- What was Jounce Therapeutics, Inc.'s free cash flow in fiscal 2022?
- Jounce Therapeutics, Inc. reported free cash flow of -$29.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$83.9 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2023. SEC
- What are Jounce Therapeutics, Inc.'s total assets?
- As of Dec 31, 2022, Jounce Therapeutics, Inc. reported total assets of $212.6 million, against $252.7 million a year earlier (-15.9%). Source: the 10-K filed with the SEC on Mar 10, 2023. SEC
- What are Jounce Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2022, Jounce Therapeutics, Inc. reported total liabilities of $29.4 million, against $28.9 million a year earlier (+1.9%). Source: the 10-K filed with the SEC on Mar 10, 2023. SEC
- What are Jounce Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Jounce Therapeutics, Inc. reported cash and cash equivalents of $150.6 million, against $95.5 million a year earlier (+57.6%). Source: the 10-K filed with the SEC on Mar 10, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1640455&period_type=annual&limit=5"Information only, not investment advice.